Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies
The recent outbreak “Coronavirus Disease 2019 (COVID-19)” is caused by fast-spreading and highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). This virus enters into the human respiratory system by binding of the viral surface spike glycoprotein (S-protein) to an angiotensi...
Gespeichert in:
Veröffentlicht in: | Journal of molecular modeling 2022-08, Vol.28 (8), p.212-212, Article 212 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The recent outbreak “Coronavirus Disease 2019 (COVID-19)” is caused by fast-spreading and highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). This virus enters into the human respiratory system by binding of the viral surface spike glycoprotein (S-protein) to an angiotensin-converting enzyme2 (ACE2) receptor that is found in the nasal passage and oral cavity of a human. Both spike protein and the ACE2 receptor have been identified as promising therapeutic targets to develop anti-SARS-CoV2 drugs. No therapeutic drugs have been developed as of today except for some vaccines. Therefore, potent therapeutic agents are urgently needed to combat the COVID-19 infections. This goal would be achieved only by applying drug repurposing and computational approaches. Thus, based on drug repurposing approach, we have investigated 16 bioactive components (
1
–
16
) from different nasal spray solutions to check their efficacies against human ACE2 and SARS-CoV2 spike proteins by performing molecular docking and molecular dynamic (MD) simulation studies. In this study, three bioactive components namely ciclesonide (
8
), levocabastine (
13
), and triamcinolone acetonide (
16
) have been found as promising inhibitory agents against SARS-CoV2 spike and human ACE2 receptor proteins with excellent binding affinities, comparing to reference drugs such as nafamostat, arbidol, losartan, and benazepril. Furthermore, MD simulations were performed (triplicate) for 100 ns to confirm the stability of
8
,
13
, and
16
with said protein targets and to compute MM-PBSA-based binding-free energy calculations. Thus, bioactive components
8
,
13
, and
16
open the door for researchers and scientist globally to investigate them against SARS-CoV2 through in vitro and in vivo analysis.
Graphical abstract |
---|---|
ISSN: | 1610-2940 0948-5023 |
DOI: | 10.1007/s00894-022-05213-9 |